BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
Rhea-AI Summary
BeyondSpring (NASDAQ: BYSI) has announced a poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation will focus on the 303 Study, an investigator-initiated study supported by Merck and BeyondSpring, examining the combination of Pembrolizumab, Plinabulin, and Docetaxel in second and third-line non-small cell lung cancer (NSCLC) patients who progressed on PD-1/PD-L1 inhibitors.
The presentation, titled "Phase 2 Study of Pembrolizumab plus Plinabulin and Docetaxel for Patients with Metastatic NSCLC," will be delivered on May 31, 2025, from 1:30 PM to 4:30 PM CDT at the McCormick Place Convention Center. The study focuses on efficacy and safety results related to immune re-sensitization in patients who progressed after first-line immune checkpoint inhibitor therapy.
Positive
- None.
Negative
- None.
News Market Reaction – BYSI
In the trading session that priced this news, BYSI declined 5.68%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 through June 3 in Chicago, IL.
Presentation details are as follows:
- Title: Phase 2 Study of Pembrolizumab (Pembro) plus Plinabulin (Plin) and Docetaxel (Doc) for Patients (Pts) with Metastatic NSCLC after Progression on First-line Immune Checkpoint Inhibitor Alone or Combination Therapy: Initial Efficacy and Safety Results on Immune Re-sensitization
- Presenter / Author : Yan Xu, Minjiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Wei Zhong, RuiLi Pan, Mengzhao Wang
- Presentation Time: Saturday, May 31, 2025, at 1:30PM to 4:30PM CDT
- Location: McCormick Place Convention Center
- Session / Track: Lung Cancer – Non-Small Cell Metastatic
- Abstract Number: 8560
- Poster Board Number: 40
About BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and a range of cancer indications. Plinabulin’s novel mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors to checkpoint inhibitors. Learn more at beyondspringpharma.com.
About 303 Study
303 Study is an open-label, single-arm Phase 2 Study of Plinabulin plus docetaxel and pembrolizumab for previously treated patients with metastatic NSCLC and progressive disease after anti-PD-(L)1 inhibitor alone or in combination with platinum-doublet chemotherapy. This study evaluates the efficacy and safety of this triple combination and is being conducted at Peking Union Medical College Hospital, Beijing, China with Dr. Mengzhao Wang, Chief of the Department of Respiratory and Critical Care Medicine, as the principal investigator and with Merck. The sample size of the study is 47 patients and all have been enrolled. The primary endpoint is investigator-based ORR (RECIST 1.1). The secondary endpoints include PFS, OS, DoR, and safety. The regimen includes Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1, Docetaxel 75 mg/m2 IV Q3W on Day 1 and Plinabulin 30mg/m2 IV Q3W on Day 1 in a 21-day cycle. The study is funded by Merck’s Investigator Studies Program and BeyondSpring with provision of study drug and financial support. The registration number is NCT05599789 on clinicaltrials.gov.
Investor Contact:
IR@beyondspringpharma.com
Media Contact:
PR@beyondspringpharma.com
